Overview on Sclerodermal Renal Crisis

Mahdi Ali M. Alyami *

Tabuk University, KSA.

Jalawi Talal A. Alotaibi

Tabuk University, KSA.

Shahad Saad A. Aljoaid

Tabuk University, KSA.

Tariq Bander F. Alanazi

Tabuk University, KSA.

Waleed Farhan D. Alshammari

Tabuk University, KSA.

Nuwayr Hamdan D. Albalawi

Tabuk University, KSA.

Reema Abdulrahman A. Alanazi

Tabuk University, KSA.

Abrar Ali M. Aldhameen

Immam Abdulrahman Bin Faisal University, Dammam, KSA.

Muflih Abdullah S. Albalawi

Tabuk University, KSA.

Mona Khalid M. Alqubali

Tabuk University, KSA.

Marawn Fahad H. Altemani

King Salman Armed Force Hospital, Tabuk, KSA.

Abeer Abdulrhman. Basmih

AlNoor specialist Hospital, Makkah, Saudi Arabia.

*Author to whom correspondence should be addressed.


Abstract

Usually, malignant high blood pressure and severe renal damage are main characters in SSc. SRCs is a relatively rare condition, found in approximately 5% of all SSc patients. This study was carried out to summarize the contemporary evidence regarding the causes, risk factors, manifestations, management and prognosis of Sclerodermal Renal Crisis‎.‎ a simple review was carried out, searching databases PubMed, Google Scholar, and EBSCO. The authors extracted the needed data and stated that SRCs continues to be a rare diagnosis affecting up to six percent of SSc patients, but has a high morbidity and death influence. SRCs presentation is varied, with hypertension, normal BP and renal insufficiency. Medics should be minded by potential SRCs presentations. Early detection and initiation of aggressive ACEi antihypertensive medication in ED could enhance patient outcomes and around 60% of SRCs patients need dialysis.

Keywords: Scleroderma, systemic sclerosis, renal crisis‎


How to Cite

Alyami, M. A. M., Alotaibi, J. T. A., Aljoaid, S. S. A., Alanazi, T. B. F., Alshammari, W. F. D., Albalawi, N. H. D., Alanazi, R. A. A., Aldhameen, A. A. M., Albalawi, M. A. S., Alqubali, M. K. M., Altemani, M. F. H. and Basmih, A. A. (2021) “Overview on Sclerodermal Renal Crisis”, Journal of Pharmaceutical Research International, 33(36B), pp. 88–95. doi: 10.9734/jpri/2021/v33i36B31954.